Long-term sildenafil added to intravenous epoprostenol in patients with pulmonary arterial hypertension.

[1]  L. Rubin.  Combination Therapy for Pulmonary Artery Hypertension: What Is the Evidence? , 2012, Cardiology.

[2]  Shengshou Hu,et al.  Combination Therapy in Pulmonary Arterial Hypertension: A Meta-Analysis , 2011, Cardiology.

[3]  W. Seeger,et al.  Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[4]  T. Fleming,et al.  Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study. , 2011, Chest.

[5]  A. Shimony,et al.  Meta-analysis of monotherapy versus combination therapy for pulmonary arterial hypertension. , 2011, The American journal of cardiology.

[6]  R. Benza,et al.  Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. , 2011, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[7]  A. Levinson,et al.  Combination therapy for the treatment of pulmonary arterial hypertension , 2011, Therapeutic advances in respiratory disease.

[8]  R. Benza,et al.  Compelling evidence of long-term outcomes in pulmonary arterial hypertension? A clinical perspective. , 2011, Journal of the American College of Cardiology.

[9]  R. Barst.  How has epoprostenol changed the outcome for patients with pulmonary arterial hypertension? , 2010, International journal of clinical practice. Supplement.

[10]  Christopher S Coffey,et al.  Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.

[11]  M. Humbert,et al.  Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.

[12]  Horst Olschewski,et al.  Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. , 2010, Journal of the American College of Cardiology.

[13]  M. Humbert,et al.  Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.

[14]  D. Badesch,et al.  Longterm Survival Among Patients with Scleroderma-associated Pulmonary Arterial Hypertension Treated with Intravenous Epoprostenol , 2009, The Journal of Rheumatology.

[15]  T. Fleming,et al.  Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. , 2008, Annals of internal medicine.

[16]  P. Escribano,et al.  Efficacy of sildenafil as a rescue therapy for patients with severe pulmonary arterial hypertension and given long-term treatment with prostanoids: 2-year experience. , 2006, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[17]  C. Ricachinevsky,et al.  Treatment of pulmonary arterial hypertension. , 2006, Jornal de pediatria.

[18]  T. Fleming,et al.  Sildenafil citrate therapy for pulmonary arterial hypertension. , 2005, The New England journal of medicine.

[19]  M. Nishimura,et al.  Addition of Oral Sildenafil to Beraprost Is a Safe and Effective Therapeutic Option for Patients with Pulmonary Hypertension , 2005, Journal of cardiovascular pharmacology.

[20]  Horst Olschewski,et al.  Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. , 2004, European heart journal.

[21]  W. Seeger,et al.  Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. , 2003, Journal of the American College of Cardiology.

[22]  S. Mehta.  Sildenafil for pulmonary arterial hypertension: exciting, but protection required. , 2003, Chest.

[23]  G. Funk,et al.  Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. , 2003, Chest.

[24]  P. Arbogast,et al.  Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. , 2003, American journal of respiratory and critical care medicine.

[25]  A. Shillington,et al.  Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.

[26]  Gilles Garcia,et al.  Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.

[27]  B. Brundage,et al.  Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. , 1997, Journal of the American College of Cardiology.

[28]  B. Groves,et al.  A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.

[29]  R. Barst,et al.  Survival in Primary Pulmonary Hypertension with Long-Term Continuous Intravenous Prostacyclin , 1994, Annals of Internal Medicine.